Clinical Efficacy and Safety of Combination Therapy with Amlodipine ...

3 downloads 0 Views 985KB Size Report
Pingjin Gao, Kezhi Mei, Hongwei Li, Qiuyan. Dai, Xingui Guo, Daifu Zhang, Zhimin Jin, Hua. You, Hong Ding, Ke Lü, Shuxian Zhou, Xiaoling. Peng, Hui Xu ...
Author's Accepted Manuscript

Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or Olmesartan /Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China Pingjin Gao, Kezhi Mei, Hongwei Li, Qiuyan Dai, Xingui Guo, Daifu Zhang, Zhimin Jin, Hua You, Hong Ding, Ke Lü, Shuxian Zhou, Xiaoling Peng, Hui Xu, Pengfei Yin, Licheng Yu, Lin Pi, Qi Hua, Ming Yang, Xiaowei Yu

www.elsevier.com/locate/cuthre

PII: DOI: Reference:

S0011-393X(15)00012-0 http://dx.doi.org/10.1016/j.curtheres.2015.09.001 CUTHRE484

To appear in:

Current Therapeutic Research

Cite this article as: Pingjin Gao, Kezhi Mei, Hongwei Li, Qiuyan Dai, Xingui Guo, Daifu Zhang, Zhimin Jin, Hua You, Hong Ding, Ke Lü, Shuxian Zhou, Xiaoling Peng, Hui Xu, Pengfei Yin, Licheng Yu, Lin Pi, Qi Hua, Ming Yang, Xiaowei Yu, Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or Olmesartan /Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China, Current Therapeutic Research, http://dx.doi.org/10.1016/j.curtheres.2015.09.001 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Clinical efficacy and safety of combination therapy with amlodipine and olmesartan or olmesartan /hydrochlorothiazide compound for hypertension: a prospective, open-label, and multicenter clinical trial in China Pingjin Gao1, Kezhi Mei2, Hongwei Li3*, Qiuyan Dai4, Xingui Guo5, Daifu Zhang6, Zhimin Jin7, Hua You8, Hong Ding 9, Ke Lü10, Shuxian Zhou11, Xiaoling Peng12, Hui Xu13, Pengfei Yin14, Licheng Yu15, Lin Pi16, Qi Hua17, Ming Yang18, Xiaowei Yu19 Author affiliations: 1 Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 2 Guangzhou Red Cross Hospital, 3 Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, 4 Shanghai General Hospital, 5 Huadong Hospital affiliated to Fudan university, 6 Shanghai Pudong New Area General Hospital, 7 Shanghai Songjiang District Central Hospital, 8 Wujiang First People’s Hospital, 9 Wuxi Second People’s Hospital, 10 Suzhou Municipal Hospital, 11 Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 12 Shenzhen Sun Yat-Sen Cardiovascular Hospital, 13 Shanghai Changning District Central Hospital, 14 Beijing Shijitan Hospital, Capital Medical University, 15 Beijing Haidian Hospital, 16 Beijing Chuyangliu Hospital, 17 Xuanwu Hospital Capital Medical University, 18 Beijing Fuxing Hospital, Capital Medical University, 19 People’s Hospital of Beijing Daxing District *Corresponding author : Hongwei Li, Department of Cardiology, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xicheng District, Beijing 100050, P.R. China (Tel: 138-0139-6679; Fax: 86-21- 6039-7399; Email: [email protected]) Running title: Combination therapy for hypertension in China

Abstract Background: Amlodipine (AML) is an initial therapy most commonly administered for hypertension patients in China. However, it is also known that AML monotherapy is often less

effective in blood pressure (BP) control. Objective: We performed a clinical study to evaluate efficacy and safety of a combination therapy with AML, olmesartan (OLM) or OLM/ hydrochlorothiazide (HCTZ) compound for Chinese patients with mild-to-moderate hypertension. Methods: In the clinical trial, the patients were initially treated with OLM 20mg/day, combined with AML 5mg/day. And then OLM was up-titrated to 40mg/day or changed to use OLM/HCTZ (20/12.5 mg/d) compound, if the patients did not reach to the target of seated diastolic BP (seDBP) < 90mmHg (